Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells.

The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and risin ...

Rusfertide could become a blockbuster therapy for polycythemia vera, H.C. Wainwright analyst Douglas Tsao wrote March 4 after the injectable hepcidin mimetic peptide hit its primary endpoint and all ...

The former Major League Baseball star spent 16 seasons with the Chicago White Sox and Detroit Tigers before coaching in ...

US clinical-stage pharma company Protagonist Therapeutics and Japan’s Takeda have announced positive top-line results for the ...

The live webcast for each event will be accessible on the Investors section of the company's website (www.agios.com) under the “Events & Presentations” tab. Replays of the webcasts will be archived on ...

JPMorgan raised the firm’s price target on Protagonist Therapeutics (PTGX) to $57 from $53 and keeps an Overweight rating on the shares. The ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX ) and Takeda (TSE:4502/NYSE:TAK ) today announced positive ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...